← All trials
NCT05405244
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 19, 2017
- Primary completion
- Sep 19, 2019
- Completion date
- Sep 19, 2019
- First posted
- Jun 6, 2022
- Last posted
- Sep 7, 2022
- Enrollment
- 55
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of North Carolina at Chapel HillLead sponsor
- University of North Carolina at Chapel HillOverall official - principal investigator
- American Diabetes AssociationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.